Seizure Burden Falls Over Time in Treatment‑Resistant Focal Epilepsy: Implications for Interpreting Open‑Label Disease‑Modifying Claims
Posted inNeurology news

Seizure Burden Falls Over Time in Treatment‑Resistant Focal Epilepsy: Implications for Interpreting Open‑Label Disease‑Modifying Claims

The HEP2 prospective cohort shows that most patients with focal treatment‑resistant epilepsy experienced substantial seizure reductions over 18–36 months; ASM additions produced modest gains but rarely achieved freedom, and device-treated patients followed similar trajectories to those without devices.
IV Thrombolysis Outperformed Endovascular Thrombectomy for Basilar Artery Occlusion in a Multicenter Cohort: What Clinicians Should Know
Posted inNeurology news

IV Thrombolysis Outperformed Endovascular Thrombectomy for Basilar Artery Occlusion in a Multicenter Cohort: What Clinicians Should Know

A 523‑patient multicenter cohort found intravenous thrombolysis alone was associated with better 3‑month functional outcomes and lower mortality than endovascular thrombectomy (± IVT) for acute basilar artery occlusion after adjustment for confounders. Results prompt cautious reappraisal of EVT vs IVT in BAO and call for randomized trials.
Giving IV Thrombolysis in the Late Window Before Transfer for Thrombectomy: Improved Recanalization and 3‑Month Outcomes in a Multicenter French Cohort
Posted inNeurology news

Giving IV Thrombolysis in the Late Window Before Transfer for Thrombectomy: Improved Recanalization and 3‑Month Outcomes in a Multicenter French Cohort

A multicenter retrospective cohort (OPEN-WINDOW) found that IV thrombolysis given beyond 4.5 hours before interhospital transfer for EVT was associated with higher rates of recanalization during transfer and better 3‑month functional outcomes without increased hemorrhagic complications.
Minimally Invasive Pancreatoduodenectomy Is Noninferior to Open Surgery for 90‑Day Complications but Raises Important Safety and Generalizability Questions
Posted inGeneral Surgery news Oncology

Minimally Invasive Pancreatoduodenectomy Is Noninferior to Open Surgery for 90‑Day Complications but Raises Important Safety and Generalizability Questions

An international randomized trial found minimally invasive pancreatoduodenectomy (mostly robotic) noninferior to open surgery for 90‑day overall complications and modestly faster functional recovery, with lower fistula and wound‑infection rates but a numerically higher 90‑day mortality.
Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals
Posted inAllergy & Immunology Neurology news

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–moderate AD.
Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
Posted innews Oncology

Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma

A phase II study in metastatic melanoma found no major differences in response, circulating T‑cell phenotypes, or proliferative signals between high‑dose and low‑dose IL‑2 after lymphodepletion and tumor‑infiltrating lymphocyte (TIL) infusion followed by pembrolizumab, suggesting low‑dose IL‑2 may be a feasible, lower‑toxicity alternative.
Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
Posted inDiabetes & Endocrinology news Rheumatology

Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility

A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher prednisolone doses, supporting further randomized trials.
Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus placebo in adults with obesity and prediabetes.